A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
NCT06817356 on ClinicalTrials.gov · last registry update 2026-07-16
An unusually large phase 2: 308 participants, more than double the 114 typical for the stage. The sponsor logged completion for 19 March 2026. Primary outcome, as filed: Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P2
- Drug
- mazdutide
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 308
- Started
- 2025-02-06
- Primary completion
- 2026-03-19 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method
Conditions studied
Alcohol Use Disorder
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.